CY1118496T1 - Φαρμακεyτικες συνθεσεις - Google Patents

Φαρμακεyτικες συνθεσεις

Info

Publication number
CY1118496T1
CY1118496T1 CY20171100099T CY171100099T CY1118496T1 CY 1118496 T1 CY1118496 T1 CY 1118496T1 CY 20171100099 T CY20171100099 T CY 20171100099T CY 171100099 T CY171100099 T CY 171100099T CY 1118496 T1 CY1118496 T1 CY 1118496T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
oral
administration
solubilization
delivery system
Prior art date
Application number
CY20171100099T
Other languages
English (en)
Inventor
Ludwig Daniel Weibel
Erik Philipp
Original Assignee
Vifor (International) Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39535152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118496(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vifor (International) Ag filed Critical Vifor (International) Ag
Publication of CY1118496T1 publication Critical patent/CY1118496T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Φαρμακευτικές συνθέσεις για χορήγηση από το στόμα, και ιδιαίτερα για χορήγηση ως σύστημα μεταφοράς από το στόμα που προορίζεται για κατάποση άμεσα ή είναι ικανό για διαλυτοποίηση στη στοματική κοιλότητα, που περιέχει οξείδιο-υδροξείδιο του σιδήρου σε υψηλή φόρτωση.
CY20171100099T 2007-11-16 2017-01-24 Φαρμακεyτικες συνθεσεις CY1118496T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07120837 2007-11-16
EP08848615.4A EP2222285B1 (en) 2007-11-16 2008-11-13 Pharmaceutical compositions
PCT/EP2008/065444 WO2009062993A1 (en) 2007-11-16 2008-11-13 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CY1118496T1 true CY1118496T1 (el) 2017-07-12

Family

ID=39535152

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171100099T CY1118496T1 (el) 2007-11-16 2017-01-24 Φαρμακεyτικες συνθεσεις
CY20181101376T CY1121230T1 (el) 2007-11-16 2018-12-19 Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου
CY20221100224T CY1125300T1 (el) 2007-11-16 2022-03-21 Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20181101376T CY1121230T1 (el) 2007-11-16 2018-12-19 Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου
CY20221100224T CY1125300T1 (el) 2007-11-16 2022-03-21 Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου

Country Status (35)

Country Link
US (13) US9561251B2 (el)
EP (6) EP3492069B1 (el)
JP (7) JP5466164B2 (el)
KR (2) KR101438071B1 (el)
CN (7) CN112022822A (el)
AR (1) AR069312A1 (el)
AU (1) AU2008322963B2 (el)
BR (1) BRPI0820308B8 (el)
CA (1) CA2700444C (el)
CO (1) CO6280398A2 (el)
CY (3) CY1118496T1 (el)
DK (4) DK3143992T3 (el)
ES (5) ES2703158T3 (el)
FI (1) FI3895699T3 (el)
GT (1) GT201000144A (el)
HK (1) HK1207298A1 (el)
HR (4) HRP20230588T3 (el)
HU (2) HUE031293T2 (el)
IL (2) IL205726A (el)
LT (3) LT3143992T (el)
MA (1) MA31898B1 (el)
MX (1) MX2010005346A (el)
MY (2) MY156383A (el)
NZ (1) NZ585435A (el)
PH (1) PH12015500727A1 (el)
PL (4) PL3895699T3 (el)
PT (5) PT3143992T (el)
RU (2) RU2493831C3 (el)
SA (1) SA112340044B1 (el)
SG (1) SG188789A1 (el)
SI (4) SI3492069T1 (el)
TN (1) TN2010000152A1 (el)
TW (2) TWI468167B (el)
WO (1) WO2009062993A1 (el)
ZA (1) ZA201004256B (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
EP2125847B1 (en) 2007-02-06 2015-06-17 Medical Research Council Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation
TWI468167B (zh) * 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
GB0814326D0 (en) 2008-08-05 2008-09-10 Medical Res Council Phosphate binding materials and their uses
EP2440210A4 (en) 2009-06-12 2014-01-29 Meritage Pharma Inc METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
KR101665968B1 (ko) * 2009-07-21 2016-10-13 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
AU2014218455B2 (en) * 2009-07-21 2016-11-24 Keryx Biopharmaceuticals, Inc. Ferric Citrate Dosage Forms
EP3073997B1 (en) * 2013-11-27 2020-06-03 Vifor (International) AG Pharmaceutical composition, comprising phosphate binder particles
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
WO2016038541A1 (en) * 2014-09-10 2016-03-17 Lupin Limited A manufacturing process for an iron containing adsorbent
JP5757493B1 (ja) * 2014-09-24 2015-07-29 富田製薬株式会社 経口型鉄分補給用固形組成物及びその製造方法
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
CN107397759A (zh) * 2016-05-19 2017-11-28 欣凯医药化工中间体（上海）有限公司 基于铁的氢氧化物－降解的碳水化合物的磷结合剂、其制备方法及其应用
WO2020025552A1 (en) 2018-07-30 2020-02-06 Interquim, S.A. Process for preparing an adsorbent for phosphate in aqueous medium
US20210308054A1 (en) * 2018-08-10 2021-10-07 Kissei Pharmaceutical Co., Ltd. Sucroferric oxyhydroxide-containing granules and pharmaceutical composition
RU2701738C1 (ru) * 2018-10-22 2019-10-01 Федеральное государственное бюджетное учреждение науки Институт химии нефти Сибирского отделения Российской академии наук (ИХН СО РАН) Способ получения композита на основе соединений железа
SG11202109323UA (en) 2019-02-28 2021-09-29 Renibus Therapeutics Inc Novel iron compositions and methods of making and using the same
US11090346B2 (en) * 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
WO2021137780A1 (en) * 2019-12-30 2021-07-08 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Preparation of film tablet composition comprising heme iron for iron deficiency
KR20220154086A (ko) * 2020-01-16 2022-11-21 비포 프레제니우스 메디컬 케어 레날 파마 리미티드 (비포 프레제니우스 메디컬 케어 레날 파마 아게) 철(iii)-옥시하이드록사이드, 수크로스 및 하나 이상의 전분의 혼합물, 바람직하게는 수크로페릭 옥시하이드록사이드의 혼합물의 입자
EP3932535A1 (en) 2020-07-01 2022-01-05 Vifor Fresenius Medical Care Renal Pharma, Ltd. Manufacturing method for polynuclear iron compounds stabilized by carbohydrates and/or humic acid
CN113171353B (zh) * 2021-04-25 2022-10-21 海南普利制药股份有限公司 一种马来酸曲美布汀片
CN115155537B (zh) * 2022-07-28 2023-05-09 安徽农业大学 FeOOH功能化腈纶纤维及其制备方法和应用
CN116196330B (zh) * 2023-03-16 2024-09-20 广东赛康制药厂有限公司 一种治疗高磷酸血症药物的制备工艺

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820740A (en) 1953-02-27 1958-01-21 Benger Lab Ltd Therapeutic preparations of iron
CH397628A (de) 1959-05-08 1965-08-31 Hausmann Ag Labor Verfahren zur Herstellung von therapeutisch verwendbaren Eisen-(III)-hydroxyd-Polymaltose-Komplexen
US3076798A (en) 1961-02-23 1963-02-05 Hausmann Lab Ltd Process for preparing a ferric hydroxide polymaltose complex
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
AT279048B (de) 1967-07-04 1970-02-25 Pharmazeutische Fabrik Montavit Gmbh Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon
US3499837A (en) 1967-11-20 1970-03-10 Johns Manville Waste water treatment phosphate removal by iron oxide
GB1249558A (en) 1969-08-19 1971-10-13 American Cyanamid Co Process for the preparation of size-controlled colloidal iron sols and their stabilized solutions
US3928581A (en) 1972-09-13 1975-12-23 Astra Laekemedel Ab Certain polymer-iron complexes for treatment of iron deficiency
US4181718A (en) 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4581141A (en) 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
US4327076A (en) 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
CH650890A5 (de) 1981-06-15 1985-08-15 Edak Ag Tragbares schutzgehaeuse fuer elektrische und elektronische geraete.
US4474859A (en) 1982-02-05 1984-10-02 Jujo Paper Co., Ltd. Thermal dye-transfer type recording sheet
JPS5973576A (ja) * 1982-09-16 1984-04-25 グラクソ・グル−プ・リミテツド ピペリジニルシクロペンタノ−ルヘプテン酸塩
JPS5976535A (ja) 1982-10-22 1984-05-01 Kureha Chem Ind Co Ltd 収着剤およびその製造法
US4788281A (en) 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
DE3422249A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US4668400A (en) 1984-06-22 1987-05-26 Veech Richard L Hemodialysis processes and hemodialysis solutions
US5248492A (en) 1986-07-03 1993-09-28 Advanced Magnetics, Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US4869828A (en) 1988-02-26 1989-09-26 Nalco Chemical Company Stabilization of iron in aqueous systems
US4970079A (en) * 1989-06-05 1990-11-13 Purdue Research Foundation Method and composition of oxy-iron compounds for treatment of hyperphosphatemia
US5213692A (en) 1991-08-28 1993-05-25 Kemiron, Inc. Process for preparing preferred iron humates
TW271400B (el) * 1992-07-30 1996-03-01 Pfizer
DE69321531T2 (de) * 1992-08-04 1999-03-04 Toda Kogyo Corp., Hiroshima Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung
DE4239442C2 (de) 1992-11-24 2001-09-13 Sebo Gmbh Verwendung eines mit polynuklearen Metalloxidhydroxiden modifizierten Adsorptionsmaterials zur selektiven Elimination von anorganischem Phosphat aus proteinhaltigen Flüssigkeiten
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
DE19547356A1 (de) * 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
NZ505123A (en) 1997-12-19 2003-07-25 Smithkline Beecham Corp Process for manufacturing bite-dispersion tablets by compressing medicaments and other ingredients into granulates then compressing the granulates and other ingredients into tablets, and the tablets thereof
GB9802201D0 (en) * 1998-02-03 1998-04-01 Cerestar Holding Bv Free-flowable directly compressible starch as binder,disintegrant and filler for compresion tablets and hard gelatine capsules
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6117451A (en) 1998-08-25 2000-09-12 Pharmalogix, Inc. Direct compression metformin hydrochloride tablets
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6156332A (en) 1999-05-27 2000-12-05 Ambi, Inc. Method and composition for masking mineral taste
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
US20020044969A1 (en) 2000-05-22 2002-04-18 Jerome Harden Method for increasing the compressibility of poorly binding powder materials
US6358526B1 (en) 2000-08-16 2002-03-19 Rexall Sundown Method of making tablets and tablet compositions produced therefrom
US6576665B2 (en) 2001-04-03 2003-06-10 Braintree Laboratories, Inc. Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption
HUP0402291A2 (hu) 2001-10-18 2005-03-29 Teva Pharmaceutical Industries Ltd. Stabilizált azithromycin összetételek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US20030190355A1 (en) 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
HUE024906T2 (en) 2003-08-26 2016-02-29 Shire Biopharmaceuticals Holdings Ireland Ltd Pharmaceutical composition containing lanthanum compounds
US6903235B2 (en) 2003-10-08 2005-06-07 Panion & Bf Biotech Inc. Pharmaceutical-grade ferric citrate
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
CN100345546C (zh) * 2004-08-25 2007-10-31 浙江震元制药有限公司 氯诺昔康口腔速崩组合物及其制备方法
CN1302772C (zh) * 2005-05-24 2007-03-07 中国人民解放军第二军医大学 阿魏酸钠口腔崩解片及其制备方法
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
US20080107787A1 (en) * 2006-11-02 2008-05-08 The Coca-Cola Company Anti-Diabetic Composition with High-Potency Sweetener
EP1932807A1 (en) 2006-12-14 2008-06-18 Novartis AG Inorganic compounds
ES2526171T3 (es) 2006-12-14 2015-01-07 Novartis Ag Adsorbente de fosfato a base de hierro (III)-carbohidratos
PL2319804T3 (pl) * 2006-12-14 2015-03-31 Elanco Tiergesundheit Ag Węglowodanowy adsorbent fosforanów oparty na żelazie (III)
AU2013203333B2 (en) 2007-11-16 2015-04-02 Vifor (International) Ag Pharmaceutical compositions
TWI468167B (zh) 2007-11-16 2015-01-11 威佛（國際）股份有限公司 藥學組成物
GB0814326D0 (en) 2008-08-05 2008-09-10 Medical Res Council Phosphate binding materials and their uses
EP3073997B1 (en) 2013-11-27 2020-06-03 Vifor (International) AG Pharmaceutical composition, comprising phosphate binder particles

Also Published As

Publication number Publication date
JP2023011873A (ja) 2023-01-24
CN111789820A (zh) 2020-10-20
US20210137973A1 (en) 2021-05-13
NZ585435A (en) 2012-07-27
PT3143992T (pt) 2019-01-10
BRPI0820308A8 (pt) 2019-10-29
CN112022821A (zh) 2020-12-04
RU2648760C3 (ru) 2019-12-16
RU2493831C3 (ru) 2017-06-08
CN104688702A (zh) 2015-06-10
EP3492069A2 (en) 2019-06-05
LT3143992T (lt) 2019-01-10
JP5466164B2 (ja) 2014-04-09
ZA201004256B (en) 2011-03-30
US20210128608A1 (en) 2021-05-06
US20220105130A1 (en) 2022-04-07
PL3143992T3 (pl) 2019-03-29
US20190117686A1 (en) 2019-04-25
MY156383A (en) 2016-02-15
ES2908719T3 (es) 2022-05-03
MX2010005346A (es) 2010-06-02
BRPI0820308B1 (pt) 2020-05-12
AU2008322963A2 (en) 2010-04-22
WO2009062993A1 (en) 2009-05-22
RU2648760C2 (ru) 2018-03-28
US9561251B2 (en) 2017-02-07
KR101438071B1 (ko) 2014-09-04
DK3895699T3 (da) 2023-06-19
IL247741B (en) 2020-11-30
HUE041429T2 (hu) 2019-05-28
EP3895700A3 (en) 2021-11-24
US10682376B2 (en) 2020-06-16
CY1121230T1 (el) 2020-05-29
TW200938210A (en) 2009-09-16
PT3492069T (pt) 2022-03-08
RU2493831C2 (ru) 2013-09-27
PL2222285T3 (pl) 2017-06-30
US10925896B2 (en) 2021-02-23
KR20100126266A (ko) 2010-12-01
JP6294260B2 (ja) 2018-03-14
PH12015500727B1 (en) 2015-12-14
JP6538734B2 (ja) 2019-07-03
PT3895700T (pt) 2023-07-19
DK2222285T3 (en) 2017-02-06
US20200316111A1 (en) 2020-10-08
US10933090B2 (en) 2021-03-02
EP3895698A3 (en) 2021-11-24
KR101590115B1 (ko) 2016-02-01
CY1125300T1 (el) 2024-02-16
SG188789A1 (en) 2013-04-30
SI2222285T1 (sl) 2017-05-31
JP2021001192A (ja) 2021-01-07
BRPI0820308B8 (pt) 2021-05-25
AU2008322963B2 (en) 2014-04-24
EP3143992B1 (en) 2018-10-17
GT201000144A (es) 2012-04-16
US20200345766A1 (en) 2020-11-05
ES2950337T3 (es) 2023-10-09
US20200316112A1 (en) 2020-10-08
JP7216055B2 (ja) 2023-01-31
EP3492069A3 (en) 2019-08-28
JP2015166359A (ja) 2015-09-24
CN112022822A (zh) 2020-12-04
AR069312A1 (es) 2010-01-13
CN106619710A (zh) 2017-05-10
HRP20181837T1 (hr) 2019-02-08
IL247741A0 (en) 2016-11-30
EP3895699A3 (en) 2021-11-24
HK1207298A1 (en) 2016-01-29
MY193729A (en) 2022-10-27
HRP20170034T1 (hr) 2017-02-24
FI3895699T3 (fi) 2023-06-20
US20170100431A1 (en) 2017-04-13
CA2700444A1 (en) 2009-05-22
SI3895699T1 (sl) 2023-08-31
AU2008322963A1 (en) 2009-05-22
CN101861146A (zh) 2010-10-13
ES2703158T3 (es) 2019-03-07
PL3492069T3 (pl) 2022-05-30
JP2017114873A (ja) 2017-06-29
JP2011503148A (ja) 2011-01-27
EP3492069B1 (en) 2022-02-16
US20220105129A1 (en) 2022-04-07
TN2010000152A1 (en) 2011-11-11
PT3895699T (pt) 2023-07-20
EP3895700A2 (en) 2021-10-20
ES2703158T8 (es) 2020-10-28
KR20130030306A (ko) 2013-03-26
MA31898B1 (fr) 2010-12-01
LT2222285T (lt) 2017-02-10
TW201509423A (zh) 2015-03-16
ES2951457T3 (es) 2023-10-23
RU2010124424A (ru) 2011-12-27
EP3895698A2 (en) 2021-10-20
IL205726A (en) 2016-09-29
EP3895699A2 (en) 2021-10-20
EP3895699B1 (en) 2023-04-26
HRP20230588T3 (hr) 2023-09-01
US20220072035A1 (en) 2022-03-10
SI3143992T1 (sl) 2019-02-28
TWI592159B (zh) 2017-07-21
EP2222285A1 (en) 2010-09-01
ES2612331T3 (es) 2017-05-16
US11013761B1 (en) 2021-05-25
IL205726A0 (en) 2010-11-30
US10780113B2 (en) 2020-09-22
JP5961601B2 (ja) 2016-08-02
US20190160096A1 (en) 2019-05-30
BRPI0820308A2 (pt) 2015-05-19
SA112340044B1 (ar) 2015-11-10
LT3492069T (lt) 2022-04-11
US10695367B2 (en) 2020-06-30
JP6764959B2 (ja) 2020-10-07
JP2019089805A (ja) 2019-06-13
US20220105131A1 (en) 2022-04-07
JP2014062120A (ja) 2014-04-10
CO6280398A2 (es) 2011-05-20
EP2222285B1 (en) 2016-12-28
HUE031293T2 (en) 2017-06-28
US10925897B2 (en) 2021-02-23
EP3143992A1 (en) 2017-03-22
DK3143992T3 (en) 2019-01-14
SI3492069T1 (sl) 2022-05-31
RU2013128356A (ru) 2014-12-27
EP3895700B1 (en) 2023-04-26
HRP20220318T1 (hr) 2022-05-13
DK3492069T3 (da) 2022-03-14
US20100247609A1 (en) 2010-09-30
TWI468167B (zh) 2015-01-11
PL3895699T3 (pl) 2023-08-14
CA2700444C (en) 2017-01-17
PH12015500727A1 (en) 2015-12-14
PT2222285T (pt) 2017-02-02
CN112022796A (zh) 2020-12-04
US11013762B1 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1118496T1 (el) Φαρμακεyτικες συνθεσεις
CY1122187T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
CY1121125T1 (el) Συνθεσεις για τη θεραπευτικη αντιμετωπιση του πονου και/ή της φλεγμονης
CY1122786T1 (el) Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης
CY1123023T1 (el) Υδατικη φαρμακευτικη μορφοποιηση ταπενταδολης για χορηγηση απο το στομα
CY1119177T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
CY1116150T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
LTPA2018502I1 (lt) Per burną vartojamos kladribino kompozicijos
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CR10975A (es) Formulaciones para el tratamiento del cancer
MX2009012690A (es) Composiciones, metodos, dispositivos y sistemas para el cuidado bucal.
EA201290984A1 (ru) Гелеобразные фармацевтические композиции, препятствующие злоупотреблению
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
IL193074A0 (en) Stable pharmaceutical formulations of montelukast sodium
BRPI0710508B8 (pt) composição de pepticorpo terapêutico liofilizado estável, kit para preparar uma composição farmacêutica aquosa, e métodos para fabricar um pepticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico reconstituído
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CY1111442T1 (el) Ενωσεις πιπεριδινης και χρησεις αυτων
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
BRPI1008821A2 (pt) Uso de uma fonte de dióxido de cloro